MyMD Pharmaceuticals (MYMD) Competitors $0.11 +0.00 (+2.64%) As of 07/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock MYMD vs. NMTR, PTPI, TRVN, PBLA, SRNE, ATXI, HEPA, BIOR, SMFL, and VIRXShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), Trevena (TRVN), Panbela Therapeutics (PBLA), Sorrento Therapeutics (SRNE), Avenue Therapeutics (ATXI), Hepion Pharmaceuticals (HEPA), Biora Therapeutics (BIOR), Smart for Life (SMFL), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. Its Competitors 9 Meters Biopharma Petros Pharmaceuticals Trevena Panbela Therapeutics Sorrento Therapeutics Avenue Therapeutics Hepion Pharmaceuticals Biora Therapeutics Smart for Life Viracta Therapeutics MyMD Pharmaceuticals (NASDAQ:MYMD) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Is MYMD or NMTR more profitable? MyMD Pharmaceuticals' return on equity of -179.05% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets MyMD PharmaceuticalsN/A -179.05% -108.14% 9 Meters Biopharma N/A -584.97%-159.45% Which has higher valuation and earnings, MYMD or NMTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyMD PharmaceuticalsN/AN/A-$4MN/AN/A9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Do institutionals and insiders believe in MYMD or NMTR? 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 2.1% of MyMD Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to MYMD or NMTR? In the previous week, MyMD Pharmaceuticals' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score. Company Overall Sentiment MyMD Pharmaceuticals Neutral 9 Meters Biopharma Neutral Which has more volatility and risk, MYMD or NMTR? MyMD Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. SummaryMyMD Pharmaceuticals beats 9 Meters Biopharma on 4 of the 6 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$258K$18.01M$5.57B$9.34BDividend YieldN/AN/A3.80%4.06%P/E RatioN/AN/A28.1019.86Price / SalesN/A18.44441.4199.96Price / CashN/AN/A35.8457.94Price / Book0.020.028.265.67Net Income-$4M-$15.34M$3.24B$257.80M7 Day Performance-13.70%-6.20%1.48%1.87%1 Month Performance-25.34%-12.29%8.07%10.92%1 Year Performance-93.88%-45.31%30.29%18.51% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.11+2.6%N/A-94.3%$258KN/A0.006High Trading VolumeNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220PTPIPetros PharmaceuticalsN/A$0.03-3.7%N/A-99.7%$901K$5.11M-0.0120Gap DownTRVNTrevena1.2043 of 5 stars$0.91flat$5.00+449.5%-85.0%$873K$443K-0.0240Gap DownPBLAPanbela Therapeutics0.2006 of 5 stars$0.17+9.8%N/A-46.9%$842KN/A0.006SRNESorrento Therapeutics0.5008 of 5 stars$0.00flatN/A-82.2%$772K$60.32M0.00800Gap DownATXIAvenue Therapeutics2.0268 of 5 stars$0.23-26.8%N/A-89.8%$743KN/A0.014Trending NewsGap UpHEPAHepion Pharmaceuticals0.1296 of 5 stars$0.06+1.7%N/A-99.9%$667KN/A-0.0120Gap UpBIORBiora Therapeutics1.8097 of 5 stars$0.15+6.5%$23.00+15,664.2%-98.1%$660K$892K-0.01120Gap UpSMFLSmart for LifeN/A$0.09+2,147.5%N/A-99.8%$637K$11.11M0.00110Gap DownVIRXViracta Therapeutics2.0213 of 5 stars$0.01-4.9%$1.75+12,673.7%-98.2%$544KN/A-0.0120Gap Down Related Companies and Tools Related Companies NMTR Alternatives PTPI Alternatives TRVN Alternatives PBLA Alternatives SRNE Alternatives ATXI Alternatives HEPA Alternatives BIOR Alternatives SMFL Alternatives VIRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYMD) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYMD Stock Alerts